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Abstract
Background: Radio-chemotherapy is one of the steps of multidisciplinary management in locally advanced
pancreatic cancer. The Epidermal Growth Factor Receptor (EGFR) plays an important role in the disease pathway.
The purpose of this prospective study is to evaluate the feasibility and the efficacy of radiotherapy in combination
with gemcitabine and EGFR targeting therapy for patients with locally advanced disease.
Materials and methods: From November 2008 through January 2012, 34 patients were included in this study.
In all cases an accurate pre-treatment staging including CT scan, Endoscopic Ultra-Sonography (EUS), 18F -
fluorodeoxyglucose (18F-FDG) PET-CT and laparoscopy with peritoneal washing was performed. External beam
radiation was delivered with a total dose of 50.4 Gy (1.8 Gy per fraction). Patients were treated using 3D- conformal
radiotherapy, and the clinical target volume was the primary tumor and involved lymph nodes. Gemcitabine
300 mg/m2 and Cetuximab were given weekly during radiation therapy.
Results: Ten patients (29.4 %) were excluded from the protocol because of the evidence of metastatic disease at
the pre-treatment staging. Three patients refused radiochemotherapy. Twenty-one patients completed the therapy
protocol. During the combined therapy grade 3–4 toxicities observed were only haematological (leukopenia 47,6 %,
trombocytopenia 4.8 %, elevated gamma-GT 23.8 %, elevated alkaline phosphatase 4,8 %). Non-haematological
toxicity grade 3–4 was never reported. Post-treatment workup showed partial response in five patients (24 %),
stable disease in 11 patients (52 %) and disease progression in 5 patients (24 %). Two-year Local Control was 49 %
(median, 18.6 months), 2-year Metastases Free Survival was 24 % (median, 10.8 months). One and two-year Overall
Survival were 66 % and 28 % respectively, with a median survival time of 15.3 months.
Conclusions: The combination of cetuximab and gemcitabine with concurrent radiation therapy provides a feasible
and well tolerated treatment for locally advanced pancreatic cancer. Patients’ selection is crucial in order to treat
patients appropriately.
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Introduction
Pancreatic Ductal Adenocarcinoma Cancer (PDAC) is
the 10th most commonly diagnosed cancer and the 4th
leading cause of cancer death in the U.S. The American
Cancer Society estimates that 48,960 new cases and
40,560 deaths will occur in the U.S. in 2015 [1].
The only chance of cure and prolonged survival for
PDAC patients (pts) is surgical resection. However, only
20 % of cases can be considered surgically resectable at
diagnosis, while approximately 30 %-40 % of patients are
affected by a locally advanced disease. The best thera-
peutic option for this large subset of patients has been
the topic of the scientific debate in the last decade. A
number of authors proposed neoadjuvant therapies for
pancreatic cancer to better achieve tumor control and
surgical radical resectability [2], as in several GI malig-
nancies [3–5].
Concomitant radio-chemotherapy (RCT) with gemci-
tabine has shown an improvement of local control and
overall survival in the neoadjuvant setting [6].
In recent years preclinical data suggest that addition of
Epidermal Growth Factor Receptor (EGFR) inhibitors can
increase the activity of the use of gemcitabine and radiation
in pancreatic cancer cell lines and tumors [7, 8].
Cetuximab, a monoclonal antibody that specifically
binds to the EGFR, overexpressed in pancreatic cancer,
has been shown in vivo and in vitro to enhance radio-
sensitivity, promote radiation induced apoptosis, decrease
cell proliferation, inhibit radiation-induced damage repair
and inhibit tumor angiogenesis [9].
The purpose of this study is to evaluate the feasibility
and the efficacy of RCT with gemcitabine in combination
with cetuximab for patients with locally advanced PDAC.
Materials and methods
The trial has been performed as a single-center one-
armed phase II study.
From November 2008 through January 2012, 34 con-
secutive patients affected by histologically proven pan-
creatic cancer fulfilling the inclusion criteria listed below
were included in the study.
Only patients that met the following inclusion criteria
were included in the treatment protocol: proven cyto-
logical or histological diagnosis of PDAC; age between
18 and 75 years; no previous RCT; 0-I ECOG perform-
ance status; adequate cardiac, liver and kidney function
and a good bone marrow reserve. Patients were included
if they had borderline resectable or unresectable pancre-
atic tumours. Definitions of borderline and unresectable
disease were as per NCCN guidelines. Borderline resect-
able tumors were defined by venous involvement of the
superior mesenteric vein (SMV) or portal vein (PV), gas-
troduodenal artery encasement, or abutment of the su-
perior mesenteric artery (SMA) up to 180°. Unresectable
disease was defined by greater than 180° of SMA involve-
ment, SMV/PV occlusion that is not amenable to recon-
struction, or aortic or inferior vena cava (IVC) invasion or
encasement.
The exclusion criteria were: resectable and metastatic
disease; previous or concomitant malignant disease; one
or more of the following clinical conditions: infection,
pregnancy or breast-feeding, liver failure, kidney failure,
Pa O2 < 65 mmHg, Pa CO2 > 40 mmHg, mental disability.
In all cases a thorough pre-treatment staging was
performed, including:
a) clinical examination (ECOG performance status);
b) complete blood tests and tumor markers (CEA,
CA 19–9, CA 125);
c) multilayer CT scan (MS-CT) with and without
contrast enhancement;
d) endoscopic ultrasonography (EUS) with fine needle
aspiration biopsy;
e) laparoscopy (LPS) with peritoneal washing;
f ) PET-CT with 18F-2-fluoro-2-deoxy-D-glucose (FDG).
Jaundiced patients underwent endoscopic biliary stenting
before or during RCT.
The design of this study was approved by the Institutional
Review Board.
Each patient underwent CT-based planning before
treatment. Each planning CT scan was obtained using a
Simens 16-CT simulator (Siemens Medical System).
Radiotherapy target volumes were established by CT
scan and PET-CT scan. The Clinical Target Volume
(CTV) included the tumor and involved lymph nodes
(>1 cm on CT scan and PET positive). The Planning
Target Volume (PTV) was defined by CTV with a safety
margin of 1 cm in all directions to include organ motion
and set-up errors. Patients were fixed during therapy by
individual immobilization devices.
External beam radiation was delivered to total dose of
50.4 Gy with fractionation of 1.8 Gy daily for 5 days a
week. Patients were treated using 3D-conformal radio-
therapy. Organs at risk for radiation-induced side effects
were contoured on the planning CT and dose volume
histograms (DVH) were calculated. Doses to the liver,
kidneys and spine were not to exceed the stated dose
tolerance guidelines used in the study. Maximum allow-
able radiation dose to the spinal cord was 40 Gy, no
more than 50 % of the total liver volume was planned to
receive more than 30 Gy (V30 < 50 %), and no more
than 30 % and 50 % of the contralateral and ipsilateral
kidney, respectively, were planned to receive more than
20 Gy (V20 < 30 % and 50 %). The minimal and maximal
doses in the target volume were specified.
All treatments were delivered with a 15-MV linear
accelerator (Varian Medical System) with a multifield
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isocentric technique using a multileaf collimator. Four
axial fields were commonly placed, although non-coplanar
techniques were also used. All fields were treated daily. A
quality-control protocol was applied for all patients with
the periodical acquisition of digital portal images to
evaluate the precision of the set-up.
Systemic therapy started the same day as radiation
therapy and consisted of Gemcitabine 300 mg/m2 given
weekly and Cetuximab given as loading dose 400 mg/m2
on day 1, and sequential Cetuximab 250 mg/m2∕week
simultaneously with radiation.
Patients were evaluated using a directed history and
physical examination weekly during treatment.
The occurrence and nature of any adverse events were
recorded according to the National Cancer Institute
Common Toxicity Criteria (version 3.0) scale.
Approximately 4 weeks after the completion of RCT,
restaging consisting of clinical examination, laboratory test,
tumor markers, CT scan, PET-CT scan was performed.
The tumor response was defined by CT scan and PET-
CT scan according to the World Health Organization.
The study protocol was approved by the independent
Ethics Committee of our University.
Results
Patients’ selection
Between November 2008 and January 2012, 34 patients
(F:18; M:16) entered in the protocol. Twenty-four (70 %)
patients were diagnosed based on cytology, ten (30 %)
patients had histologically-confirmed positive biopsy.
The median age was 68 years (range 36–75 years). All
patients showed a good performance status (ECOG
Score 0) and none of them had undergone previous
chemotherapy or radiotherapy. In almost all cases the
tumor was located in the head of the pancreas. Resectability
status was accorded to the NCCN guidelines. Eighteen pa-
tients (86 %) had locally advanced unresectable tumors,
three patients (14 %) had borderline resectable disease, on
the basis of the involvement of less than 180 degrees of the
superior mesenteric artery or involvement of the hepatic
artery within 1 cm of the celiac axis. All patients underwent
a diagnostic laparoscopy to verify occult peritoneal and/or
hepatic metastases and to perform peritoneal washing.
Laparoscopy was positive (presence of hepatic and/or peri-
toneal metastases and neoplastic cells in peritoneal wash-
ing) in 8 patients (23.5 %): neoplastic cells at peritoneal
washing in 2 pts, histologically proven hepatic metastases
in 3 pts, peritoneal carcinomatosis in 3 pts, unrecognized
on CT scan. Moreover all patients performed PET-CT
with 18F-2-fluoro-2-deoxy-D-glucose (FDG) resulting
negative for distant disease in 32 patients (94.1 %)
and positive disease in 2 (5.9 %): one patient with
pulmonary metastasis, one patient with sovraclavear
metastatic lymph node.
According to the results of preoperative workup, 10
patients (29.4 %) had a metastatic disease and were
therefore excluded from the protocol. Table 1 explains
the results of the different staging methods for the 10
patients with metastatic disease.
After pre-treatment selection 3 patients refused RCT.
Thus 21 patients were treated.
Demographic and clinical characteristics of these
patients are listed in Table 2.
Treatment-related toxicity
All twenty-one patients completed the therapy protocol.
During RCT the most frequent all-grade toxicities
were: haematological (anemia 76,2 %, leukopenia 80,9 %,
thrombocytopenia 71,4 %), nausea (47,6 %), fatigue (47,6 %)
and elevated gamma-GT levels (72,6 %).
No patient showed any clinical adverse events due to
infusion of cetuximab. Three patients (14.3 %) had grade
1 acneiform rash and three patients (14.3 %) grade 2.
Only one patient had grade 1 onychopathy.
The most common side effects during therapy were
haematological events.
G3 leukopenia and neutropenia occurred in 38,1 % and
19 % of patients respectively. Two patients (9,5 %) devel-
oped transient grade 4 leukopenia , and one patient grade
4 neutropenia not associated to fever. There were no cases
of grade 3–4 anemia and grade 4 thrombocytopenia.
Grade 3 trombocytopenia occurred in 4.8 % of patients.
Gastrointestinal toxicity consisted of nausea (33,3 % for
grade 1 and 14,3 % for grade 2), vomiting (14,3 % for grade
1 and 4,8 % for grade 2) and diarrhoea (4,8 % for grade 1).
Fatigue and anorexia of grade 1 occurred in 38,1 %
and 4,8 % of patients, and grade 2 in 9,5 % and 4,8 % of
patients respectively.
No patients developed grade 3–4 elevated AST/ALT
and total bilirubin. 4,8 % of patients had grade 2 of
hyperbilirubinaemia and 14.3 % of patients grade 2 of
hypertransaminasaemia.
Table 1 Results of the different staging methods for the
10 patients with metastatic disease
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Three patients (19 %) had grade 3 of elevated gamma-
GT and one patient (4,8 %) grade 4. Elevated alkaline
phosphatase of grade 3 occurred in one patient (4,8 %).
In ten patients with hematologic grade 3–4 toxicity
the treatment was interrupted (median time of interrup-
tions was 5 days, range 2–8 days). Granulocyte colony
stimulating factors were administered in three patients
(14.2 %) with G4 leukopenia/neutropenia. There were
no chemoradiation-associated deaths.
The toxicity data are summarized in Table 3.
Treatment efficacy
All patients enrolled were evaluated for clinical response.
The average time of restaging after radiochemotherapy
was 3.6 weeks (range 2.6-5 weeks).
Post-treatment CT scan showed that 5 patients (24 %)
had a partial response, in 11 patients (52 %) the disease
resulted stable and 5 patients (24 %) experienced disease
progression. If post-treatment PET-CT scan is considered,
all patients showed a reduction in the value of SUVmax
(Standard Uptake Value maximum).
Seven patients (33.3 %) underwent surgical radical re-
section, and one patient (14.7 %) achieved a complete
pathological response after combined radiochemotherapy.
Twenty patients (95.2 %) received further sequential
chemotherapy for a median of 4 months (range, 1 to
18 months). Fifteen patients received gemcitabine, four
received other gemcitabine-based chemotherapy, and
one received single-agent capecitabine. Eighteen (90 %)
had no grade 3 or higher toxicity during chemotherapy.
Two patients (10 %) experienced grade 3 gastrointestinal
toxicities (eg, nausea, vomiting, and/or diarrhea) that re-
quired intravenous fluids but not hospitalization. Dose
adjustments using standard dose-modification tables
were based on the worst toxicity observed during the
previous cycle.
The median follow-up was 23.3 months (range, 6 to
78 months).
Two-year Local Control (LC) was 49 % (median,
18.6 months; 95 % CI: 8.2–41), 2-year Metastases Free
Survival (MFS) was 24 % (median, 10.8 months; 95 % CI:
3.2-31.9) [Figs. 1, 2].
One-year Overall Survival (OS) and two-year OS were
66 % and 28 % respectively, with a median survival time
of 15.3 months (95 % CI:10.8–22.5) [Fig. 3].
The initial site of progression was local in 3 patients,
distant in 11 patients and local and at distant in two pa-
tients. Of patients who experienced local failure, three
failed outside the radiotherapy fields at lomboaortic
lymph nodes, two patients had ‘in-field’ recurrences. The
systemic progression affected the liver in 6 patients,
three patients showed peritoneal carcinomatosis (one
patients experienced both liver and peritoneal progres-
sion), and two patients had lung and ovarian metastases.
Four patients received palliative chemotherapy.
At the time of evaluation, three of the seven patients
who underwent radical surgery are alive, two patients
without evidence of disease, and one is continuing
chemotherapy for distant progression.
Discussion
The optimal treatment strategy for locally advanced
PDAC is still controversial, and despite considerable
progress in oncology the poor prognosis of patients has
not significantly improved. Thus there is clearly a need
for additional therapeutic strategies. Improved biologic
understanding of the disease and investigation of novel
mechanism-based therapeutics are required to facilitate
the development of more effective treatments with re-
duced toxicity. Modern radiotherapy has important roles
in controlling local disease: to prevent disease symp-
toms, increase the possibility of resection, and extend
survival. However, when combined with chemotherapy
to maximize disease control, the effectiveness of treat-
ment is limited by the radiation doses that can be given
safely, due to the risk of toxicity in surrounding radio-
sensitive abdominal structures. In our opinion, the selec-
tion of patients affected by this disease is a crucial issue
in the debate of integrated treatments. Advances in
diagnostic imaging, with the improvement in the quality
of computed tomography (CT) scanning, the input of
PET-CT scan and the use of laparoscopy make it possible.
For our diagnostic workup protocol we have combined
imaging and laparoscopy to better select patients for
Table 2 Enrolled patients’ characteristics

















Borderline resectable 3 14
Unresectable 18 86
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Fig. 1 Kaplan-Meier method for Local Control. The solid line represents
the curve of Local Control; the dashed lines are the upper and lower
limits of Local Control curve
Fig. 2 Kaplan-Meier method for Metasases Free Survival. The solid line
represents the curve of Metastases Free Survival; the dashed lines are
the upper and lower limits of the Metastases Free Survival curve
Table 3 Toxicity profile of chemoradiation with Cetuximab in all 21 patients
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 All grades
No. of events % No. of events % No. of events % No. of events % No. of events %
Hematologic
Anemia 10 47,6 6 28,6 0 0 0 0 16 76,2
Leukopenia 2 9,5 5 23,8 8 38,1 2 9,5 17 80,9
Granulocytopenia 5 23,8 8 38,1 4 19 1 4,8 18 85,7
Thrombocytopenia 12 57,2 2 9,5 1 4,8 0 0 15 71,4
Constitutional
Fatigue 8 38,1 2 9,5 0 0 0 0 10 47,6
Anorexia 1 4,8 1 4,8 0 0 0 0 2 9,5
Gastrointestinal
Nausea 7 33,3 3 14,3 0 0 0 0 10 47,6
Vomiting 3 14,3 1 4,8 0 0 0 0 4 19
Diarrhea 1 4,8 0 0 0 0 0 0 1 4,8
Liver and biliary
Elevated total bilirubin 1 4,8 1 4,8 0 0 0 0 2 9,5
Elevated AST/ALT 6 28,6 3 14,3 0 0 0 0 9 4,3
Elevated Alkaline phosphatase 5 23,8 3 14,3 1 4,8 0 0 9 4,3
Elevated Gamma-GT 6 28,8 5 23,8 4 19 1 4,8 16 76,2
Acneiform Rash 3 14,3 3 14,3 0 0 0 0 6 28,8
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radiochemotherapy and to select them for surgery
after the combined modality.
After preoperative staging, ten patients (29.4 %) had
metastatic disease and were excluded from the protocol,
while 24 patients (70.6 %) were enrolled for the
combined therapy.
Our diagnostic workup, including CT scan, PET-CT
scan and laparoscopy, could be a model useful to clini-
cians who treat pancreatic cancer.
Better patient selection and multimodality treatment are
crucial concepts to improve outcomes [10, 11]. Gemcita-
bine (difluorodeoxycytidine), an indipendent cytotoxic
agent, is a nucleoside analog with potent radiosensitizing
effects [6–8]. According to the results of randomized trials
gemcitabine provides improvement in survival and clinical
benefit compared with 5-fluorouracil (5-FU) treatment in
advanced PDAC patients [12, 13]. For this superiority as
both systemic therapy and potent radiosensitizing agent
[14], we realized a protocol of treatment that included the
use of preoperative gemcitabine-based chemoradiation.
On basis of literature data a single agent should not be
considered for locally advanced PDAC patients. Indeed
therapies towards multiple targets may be more beneficial.
New therapeutic approaches involve the identification
of a number of molecular targets that may be responsible
of the resistance of cancer cells to radiation or to
other cytotoxic agents. Among these EGFR has been
a molecular target of considerable interest and inves-
tigation [9].
Cetuximab is a monoclonal antibody that specifically
binds to the EGFR, thereby inhibiting downstream signal
transduction pathways.
Based on these considerations, we designed a clinical pro-
spective protocol consisting of preoperative gemcitabine-
based chemoradiation adding cetuximab to assess the
feasibility and efficacy of this therapeutic strategy in
patients with locally advanced pancreatic cancer.
Our regimen of weekly cetuximab and gemcitabine deliv-
ered with concurrent radiation therapy resulted in a good
profile of tolerability in patients with pancreatic cancer.
Crane et al. [15] reported the results of a phase II trial of
induction gemcitabine, oxaliplatin, and cetuximab followed
by radiation (50.4 Gy) with concurrent capecitabine and
cetuximab in 69 patients with locally advanced pancreatic
cancer. Cetuximab (500 mg/m2) was started on day 1 of
chemotherapy and was continued every 2 weeks during
chemotherapy and chemoradiotherapy. Fifty-one patients
(74 %) had unresectable tumors; 16 patients (23 %) had
borderline resectable tumors due to vascular abutment,
whereas 2 patients (3 %) had borderline resectable disease
only on the basis of advanced regional adenopathy. Median
follow-up was 16.3 months for all patients and 20.9 months
for living patients; median progression-free survival (PFS)
and OS were 12.5 and 19.2 months, respectively. In this
study, six patients (8.7 %) had infusion reactions to cetuxi-
mab, and two of these were grade 3. Acneiform rash was
54 % and 3 % for grades 2 and 3, respectively; it correlated
with improved survival. In our study only three patients
(14.3 %) had grade 2 acneiform rash, no patient showed
grade 3 toxicity. There was no correlation between
acneiform rash and clinical outcomes.
Our results agree with those of a phase I study evaluat-
ing cetuximab, gemcitabine and radiotherapy for locally
advanced pancreatic cancer [16]. Recent results published
by Arnoletti et al. have reported that the dose escalation
was performed with gemcitabine (0–300 mg/m2) and
cetuximab (400 mg/m2 loading dose and 250 mg/m2
weekly). The results of this study showed that 96 % of pa-
tients experienced grade 1–2 adverse events and 9 % had
grade 3–4 adverse events. As in our study, there were not
serious treatment-related events, and no patients deaths
were associated to drug toxicity and to radiation schedule.
In two phase I studies reported both in abstract forms,
the scheme of gemcitabine (300 mg/m2) and cetuximab
(400 mg/m2 loading dose and 250 mg/m2∕week) with
concurrent radiation therapy was tolerated and appeared
to be effective [17, 18].
Our results differ widely from those of another recently
published phase I study, in which patients with locally
unresectable pancreatic cancer were treated with gemcita-
bine (200 mg/m2 before dose escalation) plus cetuximab
(400 mg/m2 loading dose followed by 250 mg/m2∕week)
concurrent with radiation therapy (planned dose 50.4 Gy)
Fig. 3 Kaplan-Meier method for Overall Survival. The solid line
represents the curve of the Overall Survival; the dashed lines are the
upper and lower limits of the Overall Survival curve
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[19] . Of the nine patients enrolled in this study, one was
withdrawn before receiving the initial dose of cetuximab
because of a decline in performance status; the remaining
eight patients in which the tolerance to treatment was
assessed presented a various baseline performance status.
Five patients received more than the loading dose of
cetuximab, and only one patient completed all doses of
chemotherapy and radiotherapy.
The authors found a significant toxicity grade, includ-
ing a high rate of infusion reactions, and they concluded
that this combination should be approached with cau-
tion. This severe toxicity observed could be related to
the traditional radiotherapy treatment volumes, which
included primary tumor and prophylactic drainage nodes
in the definition of clinical target volumes.
In our study, on the contrary, all patients completed the
therapy protocol. We did not experience severe adverse
events, included infusion reactions. The prophylactic use
of chlorphenamine is likely to have prevented them.
The use of PET for target volume definition and delinea-
tion in GI tract tumors is only recently being investigated.
In pancreatic cancer the interest is rapidly growing. Top-
kan et al. have compared CT- and PET/CT-based target
volume delineation and the effects of these different mo-
dalities on 3D-conformal radiotherapy planning and radi-
ation doses to critical organs. The authors demonstrated
that PET-CT-based target volume contouring significantly
increases the GTV (Gross Tumor Volume) and the PTV
compared to CT-based contouring without increasing tis-
sue toxicity in a clinically meaningful way. The authors
utilized PET data and included the regional lymph nodes
which appeared to be metabolically involved on PET scan
but not on CT [20]. As this study suggests, the largest po-
tential benefit of incorporating PET into RT planning for
locally advanced pancreatic cancer may be the reduction
in geographic misses associated with CT-based planning
and the potential reduction in loco-regional treatment fail-
ure. On the basis of these considerations, we contoured
small treatment volumes, including the pancreatic tumor
and the involved lymph nodes. Radiation treatment vol-
umes were defined not only based on the CT scan, as
shown by the evidence in the literature, but also by using
biological information obtained through PET-CT scan. In
our cohort median PTV volume was 267.7 cc (range
130.6-797.6 cc). No patient developed grade 3–4 gastro-
intestinal toxicity. This may have been aided by limited-
field radiotherapy.
In our study, RCT treatment, conducted on small vol-
umes (only the areas biologically active) was safe and well
tolerated with a manageable toxicity. None of 21 patients
developed intestinal bleeding, a complication almost
constant, variable from 3 % to 20 % [12, 13, 21–27].
At the same time the reduction of radiotherapy treat-
ment volumes did not compromise the outcomes of
survival and locoregional control. The median survival
was 15.3 months, resulting improved in comparison
with other studies of the literature [12, 13, 21–27].
Crane et al. retrospectively compared the efficacy of
concurrent gemcitabine-based RCT with that of con-
current 5-FU-based RCT in patients with unresectable
pancreatic cancer. Patients treated with gemcitabine
had a median survival time of 11 months compared to
9 months of patients treated with 5-FU [12]. Brunner et al.
published a retrospective analysis of patients treated with
radiotherapy and 5-FU- or gemcitabine-based chemother-
apy followed by additional chemotherapy with gemcitabine.
In these patients the median survival time was 13 months
[13]. In a prospective randomized study Li et al. investi-
gated the efficacy of gemcitabine-concurrent RCT vs 5-FU
based-RCT for locally advanced pancreatic cancer. The
median survival was 14.5 months for gemcitabine-based
RCT patients compared with 6.7 months for 5-FU-based
RCT patients. The 1- and 2-year survival rate was 56 %
and 15 % for gemcitabine-RCT compared with 31 % and
0 % for 5-FU-RCT, respectively [21]. In Huguet et al. trial,
patients were treated with definitive gemcitabine-based
chemoradiation if no progression was noted after initial in-
duction chemotherapy. The median survival was 15 months
[22]. In McGinn et al. study, weekly full-dose gemcitabine
was administered concomitantly to involved-field irradi-
ation, with a median survival time of 11.6 months [23]. In
Muler et al. study [24] and in Kawakami et al. cohort
[25] the median survival times were 12.9 months and
7.1 months, respectively. Goldstein et al. assessed the
efficacy of a specific three-dimensional conformal radio-
therapy technique with concurrent continuous infusion of
5-FU sandwiched between gemcitabine chemotherapy in
patients with locally advanced pancreatic cancer. The
median survival time in this study was 11.7 months,
with the 1-year survival rate of 46.3 % [26]. Moreover,
the results of SCALOP trial showed that the median
overall survival was 15.2 months in the capecitabine-
based RCT group and 13.4 in the gemcitabine-based
RCT group [27].
Our study demonstrated distant relapses as domin-
ant treatment failure, emphasizing the need to find
more effective systemic agents. The improvement of
local control and, possibly, disease downstaging allow-
ing surgical resection are important endpoints. The
question remains how to improve local control with-
out worsening the tolerability of the treatments. The
use of modern radiation therapy procedures, such as
contrast enhancement four-dimensional computed tom-
ography (ce-4DCT), the radiation dose escalation of the
primary tumor with intensity modulated radiation therapy
(IMRT) and stereotactic body radiation therapy (SBRT)
and better target selection could help to solve this
problem.
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Conclusions
Our prospective study gives us the opportunity to
emphasize, first of all, that in the treatment of pancreatic
cancer, more than in others, the selection of patients,
using the most modern imaging techniques and laparos-
copy, is a crucial issue in order to treat these patients in
the most appropriate way and to make appropriate as-
sessments on patients’ compliance and response to ther-
apies. To our knowledge, this is the first study in which
this modality of patient selection is designed, allowing to
exclude from locoregional treatment patients with early
and rapidly progressive pancreatic cancer disease. Our
diagnostic workup, including CT scan, PET-CT scan and
laparoscopy, could be a model useful to clinicians who
treat pancreatic cancer to improve patients' selection.
Moreover, the combination of gemcitabine, cetuximab
with concurrent radiation therapy, with smaller treat-
ment volumes, is feasible and well tolerated, with en-
couraging results, that will allow to draw further studies
combining systemic chemotherapy to radiotherapy dose
intensified, in order to improve clinical outcomes.
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